| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Great Crested Newts - Implications for UK Businesses and Developers |
|
Useful Advices - Great Crested Newts - Implications for UK Businesses and Developers
Is your UK business likely to be affected by the Great Crested Newt? This amphibian species, legally protected in the UK under the Wildlife and According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product Countryside Act, is common in many parts of Southern and Eastern England. In addition to the animals themselves, their habitat, consisting of ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in onds and ditches where they breed and land up to 500m from their breeding ponds/ditches, is protected by legislation. The legislation was stren lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. thened in 2000 and the implications are still filtering through to business, with increasing impacts being felt particularly on business activi here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ies involving development and use of land, including brownfield sites. If you undertake an activity that harms this species or its habitat wit d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro out having first obtained a site licence from DEFRA, you are likely to break the law and potentially face a significant fine. This applies rega ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc dless of whether you already have planning consent for a development activity. So if you have a pond, ditch or other water body on or near som easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi e land you are planning to develop, are you likely to have this species? Some factors that increase the risk of Great Crested Newts being prese nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically t in a particular water body in England are as follows (in approximately decreasing order of importance):
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ 1km) of other ponds;
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi water body to other nearby ponds;
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a r clear;
Legal implications of the species being present on a site d dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod pend on the activities proposed, and professional advice should always be sought before taking any decisions that may involve protected species cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin For indicative purposes only, some of the offences relating to the Great Crested Newt can include:
tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen pture or kill;
t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel rotection;
ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust s to a place used for shelter or protection.
Many businesses have to deal with the implications of having the Great Crested Newt a y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products d other protected species present on their land, and are able to successfully address the issue to enable their proposed activities to proceed . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de egally and profitably. However, surveys and mitigation actions for this species, in common with other protected species, are limited to certai elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip seasons of the year, so it is worth starting the process of addressing any protected species issues as soon as possible to save time and money tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Medical Billing - Distributing Duties 5 More Tips for Maximum Business Success Managing Stakeholders in the Requirements Process
|